Key takeaways for Utah
- • Insulin resistance is not a labeled FDA indication for any GLP-1.
- • Improvements typically substantial (30-50% HOMA-IR reduction).
- • Treat via parent diagnosis (obesity, PCOS, T2D, prediabetes).
- • Utah Medicaid coverage rules apply for Insulin Resistance patients in Utah — see Medicaid section below.
- • 13 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for Insulin Resistance
There is no FDA indication for insulin resistance as a standalone diagnosis — it is a physiological state, not a labeled disease. GLP-1 therapy improves insulin sensitivity through weight loss, slowed gastric emptying, glucagon suppression, and beta-cell function preservation. Evidence grade: B. Patients with insulin resistance are typically treated via comorbid diagnoses (obesity, prediabetes, PCOS, T2D). HOMA-IR scores typically improve 30-50% with sustained semaglutide or tirzepatide therapy.
Utah-specific context
Utah has telehealth access concentrated in Salt Lake City, West Valley City, West Jordan metros, with additional reach to Provo and Sandy. University of Utah Health, Intermountain Healthcare is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at medicaid.utah.gov.
Utahtelehealth & pricing rules
- • Utah permits audio-only and asynchronous telehealth visits for GLP-1 care.
- • Utah allows new-patient telehealth prescribing without a prior in-person visit.
- • Typical cash GLP-1 price in Utah: ~$268/mo (compounded options often lower, brand higher).
State telehealth statutes change — verify current rules with your provider before booking.